O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Neuroscience LTC Specialist - Hartford, CT

Full-TimeDeadline 10/30/26
$116k - $166.8k/yr+ Incentive opportunity
Mid
Remote in USA+6 moreMore locations: Meriden, CT, USA | Connecticut, USA | Waterbury, CT, USA | Springfield, MA, USA | Hartford, CT, USA | Worcester, MA, USA
HybridMust reside within 50 miles of the primary city in the sales territory.
Sales & Account ManagementField Sales

About the job

Requirements
  • A minimum of 2 years of pharmaceutical or medical device sales experience.
  • Must reside within a commutable distance of 50 miles from the primary city in the sales territory.
  • Experience in pharmaceutical sales, healthcare management, or a related field.
  • A minimum of 4 years of sales experience with healthcare providers, ideally representing multiple products.
  • A thorough understanding of the long-term care environment, including regulatory requirements, operational challenges, and the clinical needs of long-term care residents.
  • Proven ability to build and maintain strategic relationships with key stakeholders within long-term care facilities.
  • Ability to thrive in an ambiguous environment undergoing transformation.
  • Proven track record in coaching, training, and mentoring peers or others.
  • Excellent verbal and written communication skills to convey complex information and engage with healthcare providers and decision-makers.
  • Commitment to ethical business practices, understanding of regulatory standards, and ability to execute business activities in compliance with company policies and guidance.
  • Ability to use competitive data, business reports, sales data, and promotional budgets to track progress and identify opportunities.
  • Knowledge of territory and business conditions that affect sales results and ability to establish near-term territory business-plan priorities.
  • Ability to respond compliantly to competitive threats and opportunities.
  • Ability to educate office staff on payer guidelines and reimbursement procedures.
  • Ability to use promotional materials effectively.
  • Ability to use internal support-team resources appropriately.
  • Ability to apply market and industry knowledge to overcome objections and influence prescribing habits.
  • Ability to identify territory professional groups and network to gain access to potential key opinion leaders.
  • Ability to build relationships with office and practice personnel and provide accurate information in response to account needs.
  • Ability to deliver balanced office calls and sales presentations using approved marketing materials and technical references, including studies and package inserts.
  • Competent knowledge of the company's products and competing products.
Responsibilities
  • Engage healthcare providers through in-person, virtual, and digital tools while providing expertise on products and their approved conditions.
  • Coordinate with local Neuroscience Specialists and cross-functional Medical Affairs and Market Access colleagues under appropriate guardrails.
  • Serve as the primary point of contact for long-term care accounts and healthcare providers.
  • Coordinate speaker programs and organize local provider groups for discussions.
  • Share opportunities and feedback with the Area Business Lead and provide local market insights to shape local strategy and team objectives.
  • Understand the long-term care environment and use that knowledge to position solutions that add value to long-term care facilities.
  • Identify and cultivate strategic relationships with administrators, directors of nursing, pharmacy managers, and other key decision-makers within long-term care facilities.
  • Develop and execute tailored communication and sales strategies aligned with each facility's operational demands, patient outcomes, and compliance objectives.
  • Provide detailed, on-label product information in accordance with approved materials and regulatory standards.
  • Address product-access issues including local payer coverage, copay options, prior-authorization requirements, formulary placement, and availability expectations.
  • Provide established guidance on patient care, system protocols, standards of care, discharge protocols, and published expert opinions.
  • Use webinars, virtual meetings, digital newsletters, and interactive online platforms to engage customers.
  • Maintain awareness of internal support-team resources and use them appropriately.
  • Build strong relationships with key office and practice personnel, take responsibility for follow-through, and provide value to accounts.
  • Deliver office calls and sales presentations using approved marketing materials and technical references to help healthcare providers enhance patient outcomes.
Desired Qualifications
  • Experience within the long-term care sector or with healthcare providers is highly advantageous.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.